View Financial HealthGenomics BioSci & Tech.Ltd 배당 및 자사주 매입배당 기준 점검 0/6Genomics BioSci & Tech.Ltd 현재 배당금을 지급하지 않습니다.핵심 정보0%배당 수익률-17.0%자사주 매입 수익률총 주주 수익률-17.0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향0%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Aug 01Upcoming dividend of NT$0.10 per share at 0.4% yieldEligible shareholders must have bought the stock before 08 August 2023. Payment date: 08 September 2023. Payout ratio is a comfortable 8.7% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Taiwanese dividend payers (5.4%). Lower than average of industry peers (2.8%).모든 업데이트 보기Recent updatesNew Risk • Aug 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$113m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$113m free cash flow). Earnings have declined by 40% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$1.09b market cap, or US$34.0m).Reported Earnings • May 19First quarter 2026 earnings released: NT$0.54 loss per share (vs NT$0.34 loss in 1Q 2025)First quarter 2026 results: NT$0.54 loss per share (further deteriorated from NT$0.34 loss in 1Q 2025). Revenue: NT$151.8m (up 25% from 1Q 2025). Net loss: NT$39.1m (loss widened 60% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 3% per year.공고 • May 13Genomics BioSci & Tech. Co.,Ltd. has completed a Follow-on Equity Offering in the amount of TWD 166.89322 million.Genomics BioSci & Tech. Co.,Ltd. has completed a Follow-on Equity Offering in the amount of TWD 166.89322 million. Security Name: Shares Security Type: Common Stock Securities Offered: 5,437,000 Price\Range: TWD 22.06 Security Name: Shares Security Type: Common Stock Securities Offered: 2,115,000 Price\Range: TWD 22.2New Risk • May 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 53% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (NT$1.62b market cap, or US$51.4m).Reported Earnings • Apr 07Full year 2025 earnings released: NT$0.54 loss per share (vs NT$3.08 loss in FY 2024)Full year 2025 results: NT$0.54 loss per share (improved from NT$3.08 loss in FY 2024). Revenue: NT$708.4m (up 47% from FY 2024). Net loss: NT$39.4m (loss narrowed 82% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.공고 • Apr 02Genomics BioSci & Tech. Co.,Ltd. has filed a Follow-on Equity Offering in the amount of TWD 0.1888 million.Genomics BioSci & Tech. Co.,Ltd. has filed a Follow-on Equity Offering in the amount of TWD 0.1888 million. Security Name: Shares Security Type: Common Stock Securities Offered: 7,552 Price(maximum): TWD 25공고 • Mar 17Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 26, 2026Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 26, 2026. Location: no,237-6, sec.1 ta t`ung rd., sijhih district, new taipei city Taiwan공고 • Nov 11Genomics Has Announces New ResearchGenomics has announced new research that suggests polygenic risk scores (PRS) can significantly improve the predictive performance of the cardiovascular disease (CVD) risk prediction tool, PREVENT. The findings were presented at the American Heart Association Conference 2025. The research shows that adding genetic risk to CVD tools can better identify individuals at risk of heart disease, with this benefit seen across ancestries. The findings support the implementation of PRS with the next generation of clinical CVD risk predictors, adding to a growing body of evidence that PRS can help improve CVD prevention, saving patient lives and improving population health. CVD is the leading cause of death in the U.S., claiming over 900,000 lives in 2023, accounting for approximately one in three deaths. There is one CVD death every 34 seconds, and someone has a heart attack every 40 seconds. The cost of heart disease in the U.S. in 2024 was over $400 billion. The key to CVD prevention is to identify people at high risk of the disease and to reduce their risk through statin therapy and lifestyle changes. The widespread use of statins for CVD prevention earlier this century has dramatically reduced CVD deaths. A meta-analysis of 25 trials involving nearly 70,000 patients with coronary heart disease found that the use of statins reduces CVD events by 25% and overall mortality by 16%. Previous studies had shown that adding polygenic risk to earlier clinical risk calculators significantly improves risk prediction for CVD. Further, 8% of individuals aged 40-69 were reclassified as higher risk in the IRT compared to PREVENT alone. These high-risk individuals are not currently flagged by PREVENT. Using these calculations, the researchers also found that over three million people aged 40-70 in the U.S. at high risk of CVD are currently invisible to the system, because genetics is not being used as part of CVD risk prediction measures. Statins are even more effective than average for people with high PRS. This means that over 100,000 people could avoid CVD-related complications over ten years if PRS were routinely added to PREVENT, followed by statin treatment for the newly classified high-risk individuals (compared to these individuals not being treated with statins). This study adds to a growing body of data that PRS can help improveCVD management and prevention. Genomics's 2021 HEART clinical trial, conducted with the United Kingdom's National Health Service (NHS), demonstrated that integrating genetic data into cardiovascular risk assessments fitted smoothly into clinical care pathways and changed patient management. The recently released 10-year plan for the NHS committed to rolling out prevention based on PRS to the whole country.New Risk • Sep 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$264m free cash flow). Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (NT$2.03b market cap, or US$67.1m).공고 • Mar 17Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 20, 2025Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 20, 2025. Location: no,237-6, sec.1 ta t`ung rd., sijhih district, new taipei city TaiwanNew Risk • Feb 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 55% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-NT$289m). Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$1.39b market cap, or US$42.4m).Reported Earnings • Apr 16Full year 2023 earnings released: NT$2.36 loss per share (vs NT$1.13 profit in FY 2022)Full year 2023 results: NT$2.36 loss per share (down from NT$1.13 profit in FY 2022). Revenue: NT$396.1m (down 5.5% from FY 2022). Net loss: NT$168.1m (down 335% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.공고 • Mar 22Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 12, 2024Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 12, 2024.New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (NT$1.44b market cap, or US$45.6m).Upcoming Dividend • Aug 01Upcoming dividend of NT$0.10 per share at 0.4% yieldEligible shareholders must have bought the stock before 08 August 2023. Payment date: 08 September 2023. Payout ratio is a comfortable 8.7% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Taiwanese dividend payers (5.4%). Lower than average of industry peers (2.8%).Valuation Update With 7 Day Price Move • Jun 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$25.70, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 44x in the Biotechs industry in Taiwan. Total returns to shareholders of 4.0% over the past three years.Reported Earnings • Apr 26Full year 2022 earnings released: EPS: NT$1.15 (vs NT$0.32 in FY 2021)Full year 2022 results: EPS: NT$1.15 (up from NT$0.32 in FY 2021). Revenue: NT$419.0m (up 7.4% from FY 2021). Net income: NT$71.6m (up 282% from FY 2021). Profit margin: 17% (up from 4.8% in FY 2021). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 100% share price gain to NT$20.30, the stock trades at a trailing P/E ratio of 55.3x. Average trailing P/E is 42x in the Biotechs industry in Taiwan. Total returns to shareholders of 190% over the past three years.Reported Earnings • Aug 15First half 2022 earnings released: EPS: NT$1.13 (vs NT$0.71 in 1H 2021)First half 2022 results: EPS: NT$1.13 (up from NT$0.71 in 1H 2021). Revenue: NT$205.2m (up 6.4% from 1H 2021). Net income: NT$67.9m (up 64% from 1H 2021). Profit margin: 33% (up from 21% in 1H 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 27Full year 2021 earnings released: EPS: NT$0.32 (vs NT$0.011 in FY 2020)Full year 2021 results: EPS: NT$0.32 (up from NT$0.011 in FY 2020). Revenue: NT$390.0m (down 12% from FY 2020). Net income: NT$18.7m (up NT$18.1m from FY 2020). Profit margin: 4.8% (up from 0.1% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.공고 • Apr 02Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 24, 2022Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 24, 2022.Valuation Update With 7 Day Price Move • Oct 19Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$16.95, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 20x in the Biotechs industry in Taiwan. Total returns to shareholders of 21% over the past three years.Reported Earnings • Aug 18First half 2021 earnings released: EPS NT$0.71 (vs NT$0.027 loss in 1H 2020)The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: NT$192.9m (down 8.3% from 1H 2020). Net income: NT$41.3m (up NT$42.9m from 1H 2020). Profit margin: 21% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 28Full year 2020 earnings released: EPS NT$0.01 (vs NT$0.31 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: NT$443.2m (up 3.6% from FY 2019). Net income: NT$619.0k (down 97% from FY 2019). Profit margin: 0.1% (down from 4.2% in FY 2019). Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.분석 기사 • Apr 27Is Genomics BioSci & Tech. Co.,Ltd.'s (GTSM:4195) 7.2% Dividend Worth Your Time?Is Genomics BioSci & Tech. Co.,Ltd. ( GTSM:4195 ) a good dividend stock? How can we tell? Dividend paying companies...공고 • Mar 11Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, May 28, 2021Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, May 28, 2021.Valuation Update With 7 Day Price Move • Feb 23Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$18.45, the stock is trading at a trailing P/E ratio of 77.6x, up from the previous P/E ratio of 65.2x. This compares to an average P/E of 40x in the Biotechs industry in Taiwan. Total return to shareholders over the past three years is a loss of 19%.Is New 90 Day High Low • Jan 28New 90-day low: NT$16.50The company is down 6.0% from its price of NT$17.60 on 30 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.분석 기사 • Jan 19Key Things To Consider Before Buying Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) For Its DividendIs Genomics BioSci & Tech. Co.,Ltd. ( GTSM:4195 ) a good dividend stock? How can we tell? Dividend paying companies...분석 기사 • Nov 25Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?Genomics BioSci & Tech.Ltd (GTSM:4195) has had a great run on the share market with its stock up by a significant 12...Is New 90 Day High Low • Nov 24New 90-day high: NT$19.50The company is up 8.0% from its price of NT$18.00 on 26 August 2020. The Taiwanese market is also up 8.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is down 1.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 4195 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 4195 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Genomics BioSci & Tech.Ltd 배당 수익률 vs 시장4195의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (4195)0%시장 하위 25% (TW)1.5%시장 상위 25% (TW)5.1%업계 평균 (Biotechs)0.4%분석가 예측 (4195) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 4195 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 4195 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 4195 TW 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: 4195 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YTW 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/21 15:38종가2026/08/21 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Genomics BioSci & Tech. Co.,Ltd.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jianzheng WuCapital Securities Corporation
Upcoming Dividend • Aug 01Upcoming dividend of NT$0.10 per share at 0.4% yieldEligible shareholders must have bought the stock before 08 August 2023. Payment date: 08 September 2023. Payout ratio is a comfortable 8.7% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Taiwanese dividend payers (5.4%). Lower than average of industry peers (2.8%).
New Risk • Aug 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$113m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$113m free cash flow). Earnings have declined by 40% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$1.09b market cap, or US$34.0m).
Reported Earnings • May 19First quarter 2026 earnings released: NT$0.54 loss per share (vs NT$0.34 loss in 1Q 2025)First quarter 2026 results: NT$0.54 loss per share (further deteriorated from NT$0.34 loss in 1Q 2025). Revenue: NT$151.8m (up 25% from 1Q 2025). Net loss: NT$39.1m (loss widened 60% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 3% per year.
공고 • May 13Genomics BioSci & Tech. Co.,Ltd. has completed a Follow-on Equity Offering in the amount of TWD 166.89322 million.Genomics BioSci & Tech. Co.,Ltd. has completed a Follow-on Equity Offering in the amount of TWD 166.89322 million. Security Name: Shares Security Type: Common Stock Securities Offered: 5,437,000 Price\Range: TWD 22.06 Security Name: Shares Security Type: Common Stock Securities Offered: 2,115,000 Price\Range: TWD 22.2
New Risk • May 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 53% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (NT$1.62b market cap, or US$51.4m).
Reported Earnings • Apr 07Full year 2025 earnings released: NT$0.54 loss per share (vs NT$3.08 loss in FY 2024)Full year 2025 results: NT$0.54 loss per share (improved from NT$3.08 loss in FY 2024). Revenue: NT$708.4m (up 47% from FY 2024). Net loss: NT$39.4m (loss narrowed 82% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
공고 • Apr 02Genomics BioSci & Tech. Co.,Ltd. has filed a Follow-on Equity Offering in the amount of TWD 0.1888 million.Genomics BioSci & Tech. Co.,Ltd. has filed a Follow-on Equity Offering in the amount of TWD 0.1888 million. Security Name: Shares Security Type: Common Stock Securities Offered: 7,552 Price(maximum): TWD 25
공고 • Mar 17Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 26, 2026Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 26, 2026. Location: no,237-6, sec.1 ta t`ung rd., sijhih district, new taipei city Taiwan
공고 • Nov 11Genomics Has Announces New ResearchGenomics has announced new research that suggests polygenic risk scores (PRS) can significantly improve the predictive performance of the cardiovascular disease (CVD) risk prediction tool, PREVENT. The findings were presented at the American Heart Association Conference 2025. The research shows that adding genetic risk to CVD tools can better identify individuals at risk of heart disease, with this benefit seen across ancestries. The findings support the implementation of PRS with the next generation of clinical CVD risk predictors, adding to a growing body of evidence that PRS can help improve CVD prevention, saving patient lives and improving population health. CVD is the leading cause of death in the U.S., claiming over 900,000 lives in 2023, accounting for approximately one in three deaths. There is one CVD death every 34 seconds, and someone has a heart attack every 40 seconds. The cost of heart disease in the U.S. in 2024 was over $400 billion. The key to CVD prevention is to identify people at high risk of the disease and to reduce their risk through statin therapy and lifestyle changes. The widespread use of statins for CVD prevention earlier this century has dramatically reduced CVD deaths. A meta-analysis of 25 trials involving nearly 70,000 patients with coronary heart disease found that the use of statins reduces CVD events by 25% and overall mortality by 16%. Previous studies had shown that adding polygenic risk to earlier clinical risk calculators significantly improves risk prediction for CVD. Further, 8% of individuals aged 40-69 were reclassified as higher risk in the IRT compared to PREVENT alone. These high-risk individuals are not currently flagged by PREVENT. Using these calculations, the researchers also found that over three million people aged 40-70 in the U.S. at high risk of CVD are currently invisible to the system, because genetics is not being used as part of CVD risk prediction measures. Statins are even more effective than average for people with high PRS. This means that over 100,000 people could avoid CVD-related complications over ten years if PRS were routinely added to PREVENT, followed by statin treatment for the newly classified high-risk individuals (compared to these individuals not being treated with statins). This study adds to a growing body of data that PRS can help improveCVD management and prevention. Genomics's 2021 HEART clinical trial, conducted with the United Kingdom's National Health Service (NHS), demonstrated that integrating genetic data into cardiovascular risk assessments fitted smoothly into clinical care pathways and changed patient management. The recently released 10-year plan for the NHS committed to rolling out prevention based on PRS to the whole country.
New Risk • Sep 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$264m free cash flow). Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (NT$2.03b market cap, or US$67.1m).
공고 • Mar 17Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 20, 2025Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 20, 2025. Location: no,237-6, sec.1 ta t`ung rd., sijhih district, new taipei city Taiwan
New Risk • Feb 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 55% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-NT$289m). Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$1.39b market cap, or US$42.4m).
Reported Earnings • Apr 16Full year 2023 earnings released: NT$2.36 loss per share (vs NT$1.13 profit in FY 2022)Full year 2023 results: NT$2.36 loss per share (down from NT$1.13 profit in FY 2022). Revenue: NT$396.1m (down 5.5% from FY 2022). Net loss: NT$168.1m (down 335% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.
공고 • Mar 22Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 12, 2024Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 12, 2024.
New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (NT$1.44b market cap, or US$45.6m).
Upcoming Dividend • Aug 01Upcoming dividend of NT$0.10 per share at 0.4% yieldEligible shareholders must have bought the stock before 08 August 2023. Payment date: 08 September 2023. Payout ratio is a comfortable 8.7% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Taiwanese dividend payers (5.4%). Lower than average of industry peers (2.8%).
Valuation Update With 7 Day Price Move • Jun 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$25.70, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 44x in the Biotechs industry in Taiwan. Total returns to shareholders of 4.0% over the past three years.
Reported Earnings • Apr 26Full year 2022 earnings released: EPS: NT$1.15 (vs NT$0.32 in FY 2021)Full year 2022 results: EPS: NT$1.15 (up from NT$0.32 in FY 2021). Revenue: NT$419.0m (up 7.4% from FY 2021). Net income: NT$71.6m (up 282% from FY 2021). Profit margin: 17% (up from 4.8% in FY 2021). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 100% share price gain to NT$20.30, the stock trades at a trailing P/E ratio of 55.3x. Average trailing P/E is 42x in the Biotechs industry in Taiwan. Total returns to shareholders of 190% over the past three years.
Reported Earnings • Aug 15First half 2022 earnings released: EPS: NT$1.13 (vs NT$0.71 in 1H 2021)First half 2022 results: EPS: NT$1.13 (up from NT$0.71 in 1H 2021). Revenue: NT$205.2m (up 6.4% from 1H 2021). Net income: NT$67.9m (up 64% from 1H 2021). Profit margin: 33% (up from 21% in 1H 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 27Full year 2021 earnings released: EPS: NT$0.32 (vs NT$0.011 in FY 2020)Full year 2021 results: EPS: NT$0.32 (up from NT$0.011 in FY 2020). Revenue: NT$390.0m (down 12% from FY 2020). Net income: NT$18.7m (up NT$18.1m from FY 2020). Profit margin: 4.8% (up from 0.1% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
공고 • Apr 02Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 24, 2022Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 24, 2022.
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$16.95, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 20x in the Biotechs industry in Taiwan. Total returns to shareholders of 21% over the past three years.
Reported Earnings • Aug 18First half 2021 earnings released: EPS NT$0.71 (vs NT$0.027 loss in 1H 2020)The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: NT$192.9m (down 8.3% from 1H 2020). Net income: NT$41.3m (up NT$42.9m from 1H 2020). Profit margin: 21% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 28Full year 2020 earnings released: EPS NT$0.01 (vs NT$0.31 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: NT$443.2m (up 3.6% from FY 2019). Net income: NT$619.0k (down 97% from FY 2019). Profit margin: 0.1% (down from 4.2% in FY 2019). Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
분석 기사 • Apr 27Is Genomics BioSci & Tech. Co.,Ltd.'s (GTSM:4195) 7.2% Dividend Worth Your Time?Is Genomics BioSci & Tech. Co.,Ltd. ( GTSM:4195 ) a good dividend stock? How can we tell? Dividend paying companies...
공고 • Mar 11Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, May 28, 2021Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, May 28, 2021.
Valuation Update With 7 Day Price Move • Feb 23Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$18.45, the stock is trading at a trailing P/E ratio of 77.6x, up from the previous P/E ratio of 65.2x. This compares to an average P/E of 40x in the Biotechs industry in Taiwan. Total return to shareholders over the past three years is a loss of 19%.
Is New 90 Day High Low • Jan 28New 90-day low: NT$16.50The company is down 6.0% from its price of NT$17.60 on 30 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
분석 기사 • Jan 19Key Things To Consider Before Buying Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) For Its DividendIs Genomics BioSci & Tech. Co.,Ltd. ( GTSM:4195 ) a good dividend stock? How can we tell? Dividend paying companies...
분석 기사 • Nov 25Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?Genomics BioSci & Tech.Ltd (GTSM:4195) has had a great run on the share market with its stock up by a significant 12...
Is New 90 Day High Low • Nov 24New 90-day high: NT$19.50The company is up 8.0% from its price of NT$18.00 on 26 August 2020. The Taiwanese market is also up 8.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is down 1.0% over the same period.